Tu1448 Intragastric Injection of Botulinum Toxin a to Treat Gastric Cancer: An Open-Label Phase II Clinical Trial

Acetylcholine in Carcinogenesis and Targeting Cholinergic Receptors in Oncology

“…[ 80–83 ] In a phase III trial, no significant difference was found in progression‐free survival or overall survival in patients with metastatic breast cancer treated with marimastat versus those who received a placebo, and marimastat treatment increased the likelihood of musculoskeletal toxicity. [ 84 ] In another study involving 239 patients with unresectable metastatic pancreatic adenocarcinoma treated with gemcitabine and marimastat, there were no significant differences in overall survival, 1‐year survival, overall response rates, progression‐free survival, or time to treatment failure between the treatment and placebo groups. [ 80,81 ] In contrast, gastric cancer patients treated with marimastat had longer median overall survival (253 d with marimastat vs 175 d with placebo) a higher 2‐yr survival rate (18% vs 5%, respectively); and significantly longer median progression‐free survival (102 d vs 84 d respectively, P = 0.009, hazard ratio = 1.32 (1.07–1.63)) (Figure 2A).…”